Sex hormones and asthma: The role of estrogen in asthma development and severity
Authors: Urszula Radzikowska, Korneliusz Golebski
Journal: Allergy (2022)

Asthma affects people of all ages and frequently persists throughout the whole life span. However, the frequency and exacerbation of asthma symptoms depend on multiple external and internal variables, fluctuating during a lifetime. Age and gender are important factors influencing asthma development and severity. In children, asthma is predominant in boys.1 After the adolescent switch, this proportion reverse, as in adulthood, more women than men are diagnosed with the disease.2 Hereford, the link between asthma development and female and male sex hormones has been proposed. The levels of estrogen and testosterone increase during maturation, with the maximum levels observed in the second decade of life, followed by a gradual decrease with age, reaching low levels during menopause. Fluctuations of estradiol and progesterone levels during the menstrual cycle were linked with the worsening of asthma symptoms in females. Serum testosterone is inversely correlated with the odds of current asthma in both women and men.3 In agreement, the prevalence of asthma rises again in males after the 50s when a decrease in testosterone levels is observed (Figure 1). The female gender is also associated with more frequent diagnoses of severe asthma,4 and decreased expression of glucocorticoid (GCs) receptors on circulating leukocytes. Severe asthma treatment strategy includes high doses of GCs, often proving inefficient. Gender-associated expression patterns of GCs receptors might be responsible for differences observed in GCs responsiveness.5 Sex hormones regulate many autoimmune and inflammatory diseases, including asthma, by modulation of various aspects of innate and adaptive immune responses. Multiple cells and tissues express estrogen and androgen (testosterone) receptors on their surface, including cells closely related to pathomechanisms of asthma, such as eosinophils, mast cells, and T cells. Estrogens are mainly considered immunoenhancers (promoting immune responses), whereas testosterones are described as immunosuppressors (suppressing immune responses). The sexual dimorphism observed in asthma prevalence is associated with the physiological production of estrogen (positive association) and testosterone (negative association) (Figure 1). Androgens (testosterone) decrease innate immune responses, whereas estrogen and progesterone enhance type 2 (T2) inflammation, the main pathophysiologic mechanism underlying the T2 high asthma phenotype.6 T2 high asthma is characterized by the disproportionate involvement of type 2 T helper (Th2) cells, type 2 innate lymphoid cells (ILC2s), eosinophils, basophils, and mast cells, accompanied by secreted by those populations T2 cytokines, such as IL-4, -5, and -13. Testosterone decreased lung ILC2 numbers and ILC2-derived IL-5 and IL-13,7 and androgens via androgen receptors signaling stabilized suppressive function of T regulatory lymphocytes.8 External suppression of sex steroid production by contraceptives in young women may improve asthma symptoms.9 In contrast, hormone-replacement therapy (HRT) used in post-menopausal women might worsen or even induce asthma. Interestingly, a distinct pheno-endotype of asthma associated with decreased estrogen levels developed after menopause, called menopausal or post-menopausal asthma, was proposed. It can be hypothesized that HRT and subsequent increase in estrogen enhance T2 responses leading to the development/exacerbation of T2 high asthma. HRT increases (HR 1.63) the risk of new asthma development. Women terminating HRT often were able to subsequently stop asthma treatment.10 17β-estradiol was higher in post-menopausal women with severe asthma when compared to mild-to-moderate asthma, assessed both in serum and in induced sputum.11 On the contrary, it has been demonstrated that premenopausal asthma in women is characterized by low estradiol concentrations and persistent neutrophilic airway inflammation, characteristic of the non-T2 asthma phenotype. The concept of premenopausal asthma requires further investigation in properly designed big cohorts to fully understand its biology and the involvement of endogenous and exogenous estrogens in eosinophilic- and neutrophilic-predominant phenotypes. In a recent study, Vijeyakumaran et al. investigated the association between T2 inflammation and estrogen receptor signaling on Th2 cells in severe asthma (Figure 2).12 In vivo, women diagnosed with severe asthma presented elevated levels of Th2 circulating cells. Increased T2 responses and IL-13 levels in the serum were related to more frequent hospitalizations, when compared to females diagnosed with mild/moderate asthma. Interestingly, the correlation between clinical asthma characteristics and Th2 cells, eosinophils, and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) mRNA levels were observed in women but not male patients. As subsequently observed in vitro, GCs and ERα agonists prevented Th2 cell apoptosis and at the same time upregulated CRTH2, IL5, and IL13 gene expression following CRTh2 activation compared with Th2 cells treated with GCs alone. This elegant study by Vijeyakumaran et al. showed that women with severe asthma had higher levels of circulating Th2 cells, which might be partially explained by estrogen-mediated enhancement of Th2 survival and T2 cytokines production. The data presented in this study contribute to a better understanding of the role of sex hormones in the pathophysiology of asthma. Further studies delineating the role of estrogens as well as contraceptives/HRT in different phenotypes of the disease and acknowledging the phase of the menstrual cycle, will shed light on the mechanisms behind the role of hormones in modulating the innate and adaptive immune responses in the pathology of asthma. Importantly, environmental exposure to estrogen-stimulating factors should not be ignored. Environmental estrogens (xenoestrogens) might enhance the development of atopic disorders, like T2-high asthma. The levels of bisphenol S and F, analogs of bisphenol A, widely used in plastic products, were higher in urine collected from females diagnosed with asthma as compared to healthy controls. At the same time, no differences were observed in males.13 We are curious and ready to learn more. The authors declare no conflict of interest regarding this manuscript.